{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:22:40Z","timestamp":1766514160930,"version":"build-2065373602"},"reference-count":7,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ajem.2019.11.005","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T11:50:17Z","timestamp":1574077817000},"page":"850.e1-850.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lactic acidemia due to an infliximab infusion reaction"],"prefix":"10.1016","volume":"38","author":[{"given":"Nicole","family":"Vigh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajem.2019.11.005_b0005","article-title":"Incidence and management of infusion reactions to infliximab in an alternate care setting","author":"Checkley","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"9","key":"10.1016\/j.ajem.2019.11.005_b0010","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/ecco-jcc\/jjv096","article-title":"Infliximab-related infusion reactions: systemic review","volume":"9","author":"Lichtenstein","year":"2015","journal-title":"J Crohns Colitis"},{"issue":"6","key":"10.1016\/j.ajem.2019.11.005_b0015","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: a large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.ajem.2019.11.005_b0020","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.ajem.2019.11.005_b0025","first-page":"381","article-title":"A multicenter retrospective experience of infliximab in Crohn\u2019s disease patients: infusion reaction rates and treatment persistency","volume":"3","author":"Keshavarzian","year":"2007","journal-title":"Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.ajem.2019.11.005_b0030","first-page":"2032","article-title":"Serum sickness- like disease after switching to biosimilar infliximab","volume":"56","author":"Scherlinger","year":"2017","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.ajem.2019.11.005_b0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.crohns.2012.10.006","article-title":"Serum sickness-like reaction due to infliximab reintroduction during pregnancy","volume":"7","author":"Grosen","year":"2013","journal-title":"J Crohn\u2019s Colitis"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675719307442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675719307442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:46:43Z","timestamp":1760024803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675719307442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0735675719307442"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2019.11.005","relation":{},"ISSN":["0735-6757"],"issn-type":[{"type":"print","value":"0735-6757"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lactic acidemia due to an infliximab infusion reaction","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2019.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}